1. Introduction

Shared Fault in Hybrid Biological Systems is an emerging principle of biotechnology law that deals with the allocation of legal responsibility when injury, damage, malfunction, or regulatory violations arise from the combined operation of biological materials and technological systems.

Hybrid biological systems integrate two or more components, such as:

Genetically modified organisms (GMOs) and artificial intelligence.

Living cells and engineered medical devices.

Biological tissues and robotic systems.

Synthetic organisms and automated laboratory equipment.

Human biological material and computational algorithms.

Bioengineered organs and electronic monitoring systems.

Microorganisms and industrial manufacturing technologies.

In these systems, harm may not result from the independent conduct of one person. Instead, it may emerge from the interaction of researchers, biotechnology companies, manufacturers, hospitals, software developers, laboratories, and regulatory authorities.

For example, consider a bioengineered organ containing living genetically modified cells connected to an AI-powered monitoring device. If the organ malfunctions because of a biological defect, a software error, and inadequate clinical supervision, several parties may share legal responsibility.

The central legal question is:

How should liability be distributed when multiple actors contribute to a single harmful outcome in a hybrid biological system?

The answer requires consideration of negligence, product liability, causation, informed consent, biosafety, environmental responsibility, intellectual property, and regulatory accountability.

2. Meaning and Nature of Shared Fault

Shared fault means that responsibility for a harmful event may be distributed among multiple parties according to their respective conduct, legal duties, causal contributions, and degree of responsibility.

It differs from ordinary individual negligence because hybrid biological systems involve interconnected technical and biological processes.

For example:

However, participation alone does not establish liability. A claimant must generally establish an applicable legal duty, breach, causation, and legally recognised damage, subject to statutory liability regimes.

3. Legal Foundations of Shared Fault

A. Joint and several liability

Joint and several liability arises when multiple defendants are legally responsible for the same injury.

Under this principle, depending on the applicable law and circumstances, an injured person may recover the full compensation from one responsible defendant, leaving the defendants to resolve contribution between themselves.

In hybrid biotechnology, this may arise when:

A manufacturer supplies defective biological material.

A software developer supplies an unreliable monitoring algorithm.

A hospital uses the system without adequate validation.

A medical professional fails to respond to warning signals.

The court must determine whether their acts or omissions jointly caused the injury.

Indian tort law recognises principles of joint tortious responsibility, although the precise basis and extent of liability depend on the facts and applicable statutory provisions.

B. Proportionate liability

Proportionate liability allocates responsibility according to the contribution of each defendant to the damage.

For example, if a bioengineered medical system fails because of several independently established negligent acts, a court may examine:

The manufacturer's contribution.

The research institution's contribution.

The software developer's contribution.

The healthcare provider's contribution.

The operator's contribution.

The allocation must be supported by evidence rather than arbitrary percentages.

A critical distinction is that proportionate liability is not automatically available in every Indian tort or consumer claim. Joint and several liability, statutory product liability, and contractual indemnity may operate differently.

C. Strict and absolute liability

Some biotechnology activities involve inherently hazardous substances or processes. In such circumstances, liability may arise even without proof of conventional negligence.

In India, the doctrine of absolute liability is particularly important for hazardous industrial activities.

This principle becomes relevant when hybrid biological systems involve:

Dangerous genetically engineered microorganisms.

Pathogenic biological materials.

Hazardous synthetic organisms.

Industrial biotechnology facilities.

Accidental biological contamination.

Environmental release of harmful engineered organisms.

D. Product liability

A hybrid biological system may be treated as a product, a service, or a combination of both.

Defective components may include:

Genetically engineered biological materials.

Artificial organs.

Implantable devices.

Laboratory instruments.

AI-enabled medical equipment.

Biological monitoring systems.

The Consumer Protection Act, 2019 provides a statutory product-liability framework under Sections 82–87.

Section 84 addresses manufacturer liability, including manufacturing defects, defective design, deviations from manufacturing specifications, breach of express warranty, and inadequate instructions or warnings. Section 85 deals with product service providers, while Section 86 addresses product sellers.

Indian Kanoon+1

4. Important Indian Case Laws

The following judgments provide the legal foundations for determining shared fault. Some concern biotechnology directly, while others establish principles applicable by analogy.

Case 1. Gene Campaign v. Union of India (2024) 2024 INSC 545

Directly relevant to GMO regulation

Court: Supreme Court of India

Decision: 23 July 2024.

Background:

The litigation concerned the environmental release approval of genetically modified mustard hybrid DMH-11.

The petitioners questioned the adequacy of biosafety assessment, regulatory supervision, scientific independence, and public participation.

The Supreme Court delivered separate opinions by Justices B.V. Nagarathna and Sanjay Karol, resulting in a split verdict.

Legal principles:

GMO approval is subject to judicial review.

Biosafety decisions must follow the applicable statutory framework.

Scientific risk assessment must be taken seriously.

Regulatory authorities must consider environmental and public-health consequences.

Transparency and institutional accountability are important in biotechnology governance.

The Court also directed the Union Government to formulate a national policy concerning GM crops.

Relevance to shared fault:

This judgment demonstrates that responsibility in hybrid biological systems cannot be examined exclusively through the conduct of private manufacturers or researchers.

Regulatory institutions also have legally reviewable responsibilities.

For example, if an engineered biological product causes environmental damage following an improperly conducted approval process, questions may arise concerning:

The research institution's testing.

The applicant company's disclosures.

The regulatory committee's assessment.

The government's supervision.

The manufacturer's subsequent conduct.

However, the judgment does not establish automatic civil compensation liability against every participating authority. The two opinions must also be read separately, together with the common directions and subsequent proceedings.

Indian Kanoon+2

Case 2. M.C. Mehta v. Union of India (1987) 1 SCC 395

Court: Supreme Court of India.

Background:

The case arose from the Oleum Gas Leak incident involving Shriram Food and Fertiliser Industries in Delhi.

The Supreme Court developed the doctrine of absolute liability for enterprises engaged in hazardous or inherently dangerous activities.

Legal principle:

An enterprise conducting hazardous activities owes an absolute and non-delegable duty to ensure that its operations do not harm the community.

It cannot escape liability merely by claiming that it exercised reasonable care.

Relevance to hybrid biological systems:

Suppose a biotechnology company operates an industrial facility containing engineered microorganisms.

A failure in biological containment, automated temperature control, or sterilisation equipment results in the release of a dangerous organism.

The following parties may have different forms of responsibility:

The biotechnology enterprise for hazardous operations.

The equipment manufacturer for defective machinery.

The laboratory for improper biological handling.

The maintenance contractor for negligent maintenance.

The enterprise's absolute liability may arise under the doctrine where the legal conditions are satisfied, independently of whether another participant also contributed to the incident.

This case is especially significant because complex industrial systems should not allow enterprises to avoid responsibility simply by dividing their operations among contractors.

ELAW: Environmental Law Alliance Worldwide

Case 3. Vellore Citizens' Welfare Forum v. Union of India (1996) 5 SCC 647

Court: Supreme Court of India.

Background:

The case concerned environmental pollution caused by tanneries in Tamil Nadu.

The Court recognised the precautionary principle and the polluter-pays principle as important elements of Indian environmental law.

Legal principle:

The polluter-pays principle requires polluting industries to bear the costs of preventing and remedying environmental damage.

The precautionary principle requires preventive action where serious environmental harm is possible, even where scientific certainty is incomplete.

Relevance to hybrid biological systems:

Consider a company manufacturing genetically modified agricultural organisms.

If the organisms escape controlled cultivation and contaminate surrounding ecosystems, liability may involve:

The producer of the organisms.

The field-testing institution.

The operator of the experimental facility.

The organisation responsible for containment.

Other parties whose legally actionable conduct contributed to the contamination.

The case supports the principle that environmental restoration costs should not automatically be transferred to affected communities.

Case 4. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999) 2 SCC 718; (2001) 2 SCC 62

Court: Supreme Court of India.

Background:

The litigation concerned industrial activity potentially threatening drinking-water reservoirs.

The Supreme Court examined the importance of scientific evidence in environmental decision-making.

Legal principle:

The Court emphasised:

The importance of scientific expertise.

The precautionary principle.

The need to consider environmental risks before granting approvals.

The difficulty of adjudicating technically complex disputes without reliable scientific assistance.

Relevance to shared fault:

Hybrid biological systems frequently involve scientific uncertainty.

For example, an engineered microorganism may interact unpredictably with an existing ecosystem.

The claimant may need to establish whether the harm resulted from:

Genetic modification.

Inadequate containment.

Environmental conditions.

Failure of monitoring equipment.

Negligent institutional supervision.

This judgment supports the importance of expert evidence in determining technical causation and assessing the responsibility of different participants.

Indian Kanoon+1

Case 5. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Court: Supreme Court of India.

Background:

The case involved medical treatment performed beyond the scope of the patient's consent.

Legal principle:

The Supreme Court explained the requirements of valid informed consent, including the patient's understanding of the nature and purpose of the proposed treatment.

Relevance to hybrid biological systems:

Suppose a patient agrees to receive a conventional medical implant, but the hospital introduces an experimental bioengineered component without properly explaining its nature and risks.

Potential liability may arise against:

The treating doctor.

The hospital.

The research institution.

The biotechnology company, where its conduct independently gives rise to liability.

The case establishes that technical innovation does not eliminate the obligation to respect patient autonomy.

A signed consent form does not automatically excuse negligent treatment or undisclosed material risks.

Indian Kanoon

Case 6. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

Court: Supreme Court of India.

Background:

The case examined the legal standard for establishing medical negligence.

Legal principle:

The Supreme Court discussed the professional standard of care and the distinction between an adverse medical outcome and legally actionable negligence.

Relevance to hybrid biological systems:

A doctor using an AI-assisted biological implant is not automatically negligent merely because the technology fails.

The court must consider whether the doctor:

Exercised reasonable professional judgment.

Properly monitored the patient.

Responded to available warnings.

Followed accepted clinical procedures.

Recognised the limitations of the technology.

The judgment helps distinguish medical negligence from unavoidable technological failure.

It also prevents the automatic transfer of all responsibility to medical professionals when a defect originates with the manufacturer or developer.

5. Comparative International Case Laws

Case 7. Wilsher v. Essex Area Health Authority [1988] AC 1074

Jurisdiction: United Kingdom.

Background:

The case concerned an infant who suffered serious injury following premature birth and medical treatment.

Several possible causes were considered, including negligent medical treatment.

Legal principle:

The claimant must establish the necessary causal connection between the defendant's negligence and the injury. The existence of several possible causes does not automatically establish liability against a particular defendant.

Relevance:

In a hybrid biological system, a patient's injury may result from multiple potential causes:

Biological instability.

Device malfunction.

Software error.

Medication interaction.

Negligent medical supervision.

The case illustrates why scientific evidence and careful causal analysis are essential before allocating fault.

Case 8. Fairchild v. Glenhaven Funeral Services Ltd [2002] UKHL 22

Jurisdiction: United Kingdom.

Background:

The case concerned workers who developed mesothelioma after exposure to asbestos while working for different employers.

It was scientifically impossible to identify which particular exposure had caused the disease.

Legal principle:

In the exceptional circumstances of the case, the House of Lords accepted material increase in risk as a sufficient basis for causation.

Relevance:

Hybrid biological systems may produce similar evidentiary difficulties.

For instance, a patient may have received biological materials from multiple research stages, and the precise origin of contamination may be scientifically difficult to establish.

The case provides a comparative illustration of how courts may respond to exceptional scientific uncertainty.

It does not establish a general rule that mere contribution to risk is sufficient for liability in every biotechnology dispute.

Case 9. Monsanto Canada Inc. v. Schmeiser [2004] 1 SCR 902

Court: Supreme Court of Canada.

Background:

The dispute involved genetically modified canola plants containing Monsanto's patented technology found growing on Schmeiser's property.

Legal principle:

The Court examined patent infringement and the exercise of control over patented genetic technology.

Importantly, the case was not a general decision establishing environmental or personal-injury liability for genetic contamination.

Relevance:

The case demonstrates that biological material and technological inventions can create complicated legal relationships involving:

Patent ownership.

Biological propagation.

Commercial exploitation.

Agricultural practices.

Control over genetic technology.

In a hybrid biological system, ownership of a patented biological component does not, by itself, establish responsibility for every harmful outcome involving that component.

6. Allocation of Shared Fault Among Stakeholders

The allocation of fault requires examination of the legal responsibilities of each participant.

The allocation must depend on the actual causal contribution and the legal duty owed by each party.

7. Statutory Framework in India

Several Indian statutes may apply to shared fault in hybrid biological systems.

A. Environment (Protection) Act, 1986

This Act provides the principal framework for environmental protection and regulation of hazardous activities.

Its importance includes:

Regulation of hazardous biological activities.

Environmental safeguards.

Governmental inspection and enforcement.

Prevention of environmental contamination.

B. 1989 Genetically Engineered Organisms Rules

The Rules on the Manufacture, Use, Import, Export and Storage of Hazardous Micro-organisms, Genetically Engineered Organisms or Cells regulate activities involving genetically engineered organisms.

They establish regulatory responsibilities involving institutions such as:

Institutional Biosafety Committees (IBSCs).

Review Committee on Genetic Manipulation (RCGM).

Genetic Engineering Appraisal Committee (GEAC).

These institutions have different functions concerning research, safety assessment, and approval.

Where a hybrid biological system involves genetically engineered organisms, non-compliance with applicable biosafety requirements may become relevant to determining fault.

C. Consumer Protection Act, 2019

The product-liability provisions are particularly important.

Section 82: Application of product-liability provisions.

Section 83: Product-liability actions.

Section 84: Manufacturer liability.

Section 85: Product service provider liability.

Section 86: Product seller liability.

Section 87: Exceptions to product-liability actions.

For example, where an AI-enabled artificial organ contains a defective biological component, the claimant may examine whether the manufacturer, service provider, or seller is legally responsible.

D. Biological Diversity Act, 2002

The Biological Diversity Act, as amended, provides a framework for conservation of biological diversity, sustainable use, and associated benefit-sharing arrangements.

It may become relevant where hybrid biological research uses biological resources governed by the Act.

E. Constitution of India

Three constitutional provisions are particularly important:

Article 14: Protection against arbitrary governmental action.

Article 21: Protection of life and personal liberty, including judicially recognised environmental and health protections.

Article 48A: State responsibility concerning environmental protection.

Article 51A(g) also recognises the fundamental duty of citizens to protect and improve the natural environment.

8. Causation: The Most Difficult Issue

Causation is one of the most complicated issues in hybrid biological litigation.

A conventional negligence claim generally requires proof of:

Duty of care.

Breach of duty.

Causation.

Legally recognised damage.

In hybrid systems, establishing causation becomes difficult because biological and technological components interact.

Illustration:

A genetically engineered tissue implant fails after installation in a patient.

Investigations identify three possible defects:

The biological material was unstable.

The monitoring software generated incorrect information.

The hospital failed to respond to an abnormal signal.

The court must determine whether these failures independently or collectively caused the injury.

Methods of establishing causation

1. Scientific evidence

Expert testimony may establish the relationship between biological defects and resulting injury.

2. Technical examination

Hardware, software logs, laboratory records, and device maintenance records may identify technical failures.

3. Clinical evidence

Medical records may demonstrate whether professional negligence contributed to the injury.

4. Regulatory documentation

Biosafety approvals, testing reports, and inspection records may establish whether mandatory safeguards were followed.

5. Chain-of-custody evidence

Biological samples and engineered materials should be traceable throughout their research, manufacture, transport, and clinical use.

9. Defences Against Shared-Fault Claims

A defendant may rely on several legal defences, depending on the applicable statute and cause of action.

A. Absence of negligence

A manufacturer may demonstrate that it complied with the applicable safety standards and that the injury resulted from an unforeseeable event.

This defence does not automatically defeat statutory strict or absolute liability.

B. Independent intervening cause

A defendant may argue that an independent event broke the causal connection between its conduct and the resulting injury.

C. Contributory negligence

Where legally applicable, the defendant may establish that the injured person contributed to the harm through unreasonable conduct.

D. Misuse or unauthorised modification

A product may have been altered or used contrary to its intended instructions.

Section 87 of the Consumer Protection Act, 2019 contains relevant statutory exceptions.

E. Scientific uncertainty

A defendant may argue that the available scientific evidence cannot establish the alleged causal relationship.

However, scientific uncertainty is not an automatic defence to precautionary environmental obligations or applicable statutory liability.

10. Cross-Border Shared Fault in Hybrid Biological Systems

Hybrid biotechnology frequently involves international collaboration.

For example:

A genetic component is developed in India.

Biological samples are collected in Australia.

AI software is developed in the United States.

The medical device is manufactured in Germany.

The final system is used in a hospital in India.

If the system causes injury, several legal systems may become relevant.

Major legal questions

1. Applicable law

Which country's law governs the negligence or product-liability claim?

2. Jurisdiction

Which court has authority to hear the dispute?

3. Contractual responsibility

Do research agreements or manufacturing contracts contain indemnity provisions?

4. Regulatory responsibility

Were mandatory Indian biosafety and medical-device requirements satisfied?

5. Evidence

Can foreign laboratories, manufacturers, and software developers be required to provide relevant technical records?

6. Enforcement

Can a judgment or compensation award be enforced against a foreign defendant?

The doctrine of dépeçage may be relevant: different issues within the same dispute may be governed by different laws.

For example, contractual obligations, personal-injury liability, privacy, intellectual property, and environmental damage may require separate choice-of-law analysis.

11. Major Challenges in Determining Shared Fault

One particularly important issue is evidence asymmetry. Patients and affected communities may not have access to proprietary genetic information, algorithmic records, or laboratory reports.

Courts should therefore carefully consider disclosure obligations, expert evidence, and applicable evidentiary presumptions.

12. Recommendations for a Better Shared-Fault Framework

A comprehensive legal framework should include the following safeguards.

1. Mandatory responsibility mapping

Every hybrid biological project should identify the legal responsibilities of researchers, manufacturers, software developers, hospitals, and operators.

2. Joint safety documentation

Biological and technological components should undergo coordinated risk assessment.

3. Traceability requirements

Every biological component should have documented records of its origin, modification, testing, transportation, and use.

4. Independent audits

High-risk systems should undergo independent scientific and technical assessments.

5. Mandatory incident reporting

Serious biological or technological failures should be reported to the relevant regulatory authorities.

6. Liability insurance

High-risk biotechnology enterprises should consider appropriate insurance and compensation arrangements.

7. Evidence preservation

Laboratory records, software logs, biological samples, and device maintenance information should be preserved following serious incidents.

8. Clear contractual allocation

Research collaborations and manufacturing contracts should clearly specify indemnity, insurance, disclosure, and post-market monitoring obligations.

Importantly, contractual allocation cannot automatically remove statutory duties or the rights of injured third parties.

13. Critical Legal Analysis

The central weakness of traditional liability law is that it often assumes that a harmful outcome can be traced to an identifiable human act or defective product.

Hybrid biological systems challenge that assumption.

A biological component may interact with a technological component in ways that cannot be understood by examining either component independently.

For instance, a genetically engineered cell may behave differently when connected to an electronic monitoring system under particular environmental conditions.

If the resulting injury involves biological instability, algorithmic error, and negligent supervision, a single-defendant approach may inadequately address the legal problem.

Three principles are therefore essential:

Responsibility according to control: Parties should be assessed according to their authority over the relevant risk.

Responsibility according to contribution: Legally relevant causal contributions should be identified.

Responsibility according to statutory duty: No party should escape an independently imposed legal obligation merely because another participant also contributed to the harm.

There is, however, an important distinction between this proposed integrated framework and existing judicial precedent: Indian courts have not yet established a comprehensive, biotechnology-specific doctrine of shared fault covering all hybrid biological systems.

The existing doctrines must therefore be applied carefully to the particular facts.

14. Conclusion

Shared Fault in Hybrid Biological Systems represents an important emerging issue in biotechnology law.

As biological materials become integrated with AI, robotics, electronic devices, synthetic organisms, and automated research systems, determining responsibility for harmful outcomes becomes increasingly complicated.

Indian legal principles provide several foundations for addressing these disputes.

M.C. Mehta v. Union of India establishes absolute liability for qualifying hazardous activities. Vellore Citizens' Welfare Forum v. Union of India strengthens environmental accountability. A.P. Pollution Control Board v. Nayudu addresses scientific uncertainty. Samira Kohli v. Dr. Prabha Manchanda protects informed consent, while Jacob Mathew v. State of Punjab provides guidance on professional negligence.

Most directly, Gene Campaign v. Union of India (2024) demonstrates the importance of biosafety assessment, regulatory accountability, and judicial review in modern biotechnology.

Ultimately, shared fault should be determined through a combination of causal contribution, professional responsibility, statutory obligations, product liability, and the nature of the hazardous activity.

The objective is to ensure that technological complexity does not become a legal excuse for avoiding accountability.

15. Important Case Laws for Examination and Research

Primary research sources:

Supreme Court judgment – Gene Campaign (2024).

M.C. Mehta – Absolute Liability judgment.

A.P. Pollution Control Board v. Nayudu.

Samira Kohli – Informed Consent.

Consumer Protection Act, 2019 – Product Liability.

Legal liability for harm caused by AI in healthcare – Research review.

Research conclusion: Shared fault in hybrid biological systems requires a multidisciplinary approach integrating biotechnology law, environmental law, medical negligence, product liability, and international private law. Existing precedents offer the foundation, but a specialised statutory framework for allocating responsibility across interconnected biological and technological components remains an important area for legal development.